Upcoming Webinars
Most Recent
Oct 2020
The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.
Oct 2020
In this webinar, we will be discussing this issue in relation to cancer immunotherapy. An overview of the survival extrapolation methods which could be used for cancer immunotherapies will be presented along with an assessment of their strengths and limitations. Finally, the presenters will provide attendees with some pointers to help with the selection of appropriate survival extrapolation models for these agents.
Sep 2020
To advocate for a meaningful use of PROs to best reflect patient reality, patient advocates need to understand what PROs are, how PROs are being measured, and how they can bring the patient perspective into development, use and reporting of PRO measurements. This information will be presented across a 3-part webinar series.
Sep 2020
There is growing interest in the use of open source models (OSMs) for cost-effectiveness analysis. In this session, the leaders of a new Special Interest Group (SIG) will introduce the general ISPOR membership to OSMs, providing an overview of some of the perceived benefits and potential barriers to their adoption. The presenters will share the findings of a recent survey, relaying ISPOR members’ experiences and expectations about OSMs. The webinar will be used to help shape the direction of future events and the focus of the SIG.
Sep 2020
Certara’s extensive experience with the recently accessible French administrative healthcare database (SNDS) has provided key insights into how the database can be used for a larger impact on patient access, health technology and public health assessments
Sep 2020
Evolving data from COVID-19 tell the story we already know: the impact of this disease affects people – especially people of color - disproportionately, both in terms of risk and prevalence, as well as access to care and outcomes. In considering VA/HTA approaches, as well as in discerning how to apply such findings, how must we address questions of ethics and equity?
Economic Evaluation
Sep 2020
There is growing interest in the use of open source models (OSMs) for cost-effectiveness analysis. In this session, the leaders of a new Special Interest Group (SIG) will introduce the general ISPOR membership to OSMs, providing an overview of some of the perceived benefits and potential barriers to their adoption. The presenters will share the findings of a recent survey, relaying ISPOR members’ experiences and expectations about OSMs. The webinar will be used to help shape the direction of future events and the focus of the SIG.
Apr 2020
This timely webinar will highlight an initiative under development to create an insurance scheme in African countries to provide emergency financing for disease outbreaks. Country-level engagement to tailor the scheme to country needs and costing of outbreak responses to inform estimates of premiums will be specifically addressed.
Apr 2020
ISPOR—the professional society for health economics and outcomes research (HEOR), announced the publication of its 2020 Top 10 HEOR Trends report early this year. In the report, the Society has identified the top 10 HEOR trends that will shape the field and influence healthcare over 2020 and the near future.
Health Technology Assessment
Aug 2020
In this session, experts from Latin America, Asia-Pacific and EMEA will discuss the role of HTA in UHC, including priority setting, coverage and financing, and share their experience in effective application of HTA to support designing benefits package for UHC while tackling the encountered challenges.
Apr 2020
Health technology assessment (HTA) is gaining widespread acceptance and plays a vital role in healthcare decision making in many countries across the Asia Pacific region. In order to meet the changing demands of patients in light of new health technology innovations, HTA processes have needed to adapt. In this webinar, leading HTA experts from Thailand and South Korea will provide updates on recent developments in their countries’ HTA processes to strengthen patient access to innovative health technologies.
Real-World Data & Information Systems
Sep 2020
Certara’s extensive experience with the recently accessible French administrative healthcare database (SNDS) has provided key insights into how the database can be used for a larger impact on patient access, health technology and public health assessments
Aug 2020
In this webinar, a holistic multi-stakeholder discussion about the stage of RWE and how its use could improve the performance of healthcare systems in LATAM, including priority setting, health technology assessment (HTA), effectiveness and safety measurement, and innovative access models.
Patient-Centered Research
Sep 2020
To advocate for a meaningful use of PROs to best reflect patient reality, patient advocates need to understand what PROs are, how PROs are being measured, and how they can bring the patient perspective into development, use and reporting of PRO measurements. This information will be presented across a 3-part webinar series.
Aug 2020
In this session, expert speakers from the Asia Pacific region will discuss the importance, strengths and limitations of PROs, and use case studies to illustrate how to develop valid PRO measures and how PROs support research and decision-making.
Jul 2020
The purpose of this webinar is to present the ISPOR definition of “patient engagement in research.” The definition was derived from a multi-step process, including a systematic review and qualitative analysis of existing definitions, and a multi-stakeholder review.
Feb 2019
Jan 2019
Methodical & Statistical Research
Health Policy & Regulatory
Oct 2020
The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.
Study Approaches
Oct 2020
In this webinar, we will be discussing this issue in relation to cancer immunotherapy. An overview of the survival extrapolation methods which could be used for cancer immunotherapies will be presented along with an assessment of their strengths and limitations. Finally, the presenters will provide attendees with some pointers to help with the selection of appropriate survival extrapolation models for these agents.
Jun 2020
This webinar will explore why and how to use qualitative research methods in conjunction with discrete choice experiments in healthcare. Speakers will discuss formative qualitative research for the identification and generation of attributes and levels and qualitative research for testing survey comprehension and decision-making processes.
Apr 2020
This webinar will explore the value and challenges of linking administrative claims data to additional data sources in order to provide a more comprehensive look at the patient journey through a disease state. Data linkage types, techniques and best practices will be discussed.
Sep 2020
Evolving data from COVID-19 tell the story we already know: the impact of this disease affects people – especially people of color - disproportionately, both in terms of risk and prevalence, as well as access to care and outcomes. In considering VA/HTA approaches, as well as in discerning how to apply such findings, how must we address questions of ethics and equity?
Aug 2020
The methods, assumptions, and inputs to Value Assessment (VA) and Health Technology Assessment (HTA) are an evolving debate in the US, as we seek to balance questions of population health-driven resource allocation with the unique needs of health system, employer, payer, and societal decision-making and the emerging science of patient heterogeneity and precision medicine.
Jul 2020
The initial webinar in the series will set the stage with an overview of current issues that the pandemic presents for the assessment of new technologies to prevent, treat, and potentially cure COVID-19, as well as the policy and implementation challenges.
Jul 2020
The far-reaching impacts of a pandemic on the US healthcare industry have tremendous implications for pharmaceutical and medical device utilization. Join this session to learn about the short-and long-term effects of a pandemic on healthcare utilization to inform pharmaceutical and medical device companies on how they may need to adjust their analyses of real-world data.
May 2020
Virtual ISPOR 2020 Preconference Plenary Session - Keynote Address: COVID-19: Accelerating the Evidence to Inform our Response Mark McClellan, MD, PhD, Director, Duke-Margolis Center for Health Policy, Washington, DC, USA Panel: COVID-19: A Global Call to Action for Health Economics & Outcomes Researchers
Need More Information or Have Questions?
Contact us for more information on ISPOR education and training.